Mantle cell lymphoma staging

Jump to navigation Jump to search

Mantle cell lymphoma Microchapters


Patient Information


Historical Perspective




Differentiating Mantle cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice


History and Symptoms

Physical Examination

Laboratory Findings



Echocardiography and Ultrasound

CT scan


Other Imaging Findings

Other Diagnostic Studies


Medical Therapy



Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mantle cell lymphoma staging On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Mantle cell lymphoma staging

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mantle cell lymphoma staging

on Mantle cell lymphoma staging

Mantle cell lymphoma staging in the news

Blogs on Mantle cell lymphoma staging

Directions to Hospitals Treating Mantle cell lymphoma

Risk calculators and risk factors for Mantle cell lymphoma staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2] Ali Akram, M.B.B.S.[3]


According to the Lugano classification, there are four stages of mantle cell lymphoma based on the number of nodes and extranodal involvement.


Staging for mantle cell lymphoma is provided in the following table:[1][2]

Revised staging system for primary nodal lymphomas (Lugano classification)
Stage Involvement Extranodal (E) status
I One node or a group of adjacent nodes Single extranodal lesions without nodal involvement
II Two or more nodal groups on the same side of the diaphragm Stage I or II by nodal extent with limited contiguous extranodal involvement
II bulky* II as above with "bulky" disease Not applicable
III Nodes on both sides of the diaphragm; nodes above the diaphragm with spleen involvement Not applicable
IV Additional noncontiguous extralymphatic involvement Not applicable


  1. Cheson, Bruce D.; Fisher, Richard I.; Barrington, Sally F.; Cavalli, Franco; Schwartz, Lawrence H.; Zucca, Emanuele; Lister, T. Andrew; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute (2014-09-20). "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 32 (27): 3059–3068. doi:10.1200/JCO.2013.54.8800. ISSN 1527-7755. PMID 25113753.
  2. Ying ZT, Zheng W, Wang XP, Xie Y, Tu MF, Lin NJ, Ping LY, Liu WP, Deng LJ, Zhang C, Zhu J, Song YQ (July 2012). "The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma". Chin J Cancer. 31 (7): 348–53. doi:10.5732/cjc.011.10469. PMC 3777499. PMID 22704490.

Template:WikiDoc Sources